Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

CAR-T Meeting 2024 | Management strategies for acute and chronic GvHD following alloSCT

Anna Czyz • 17 Feb 2024
CAR-T Meeting 2024
General Belumosudil Ruxolitinib

In this video, Anna Czyz, MD, PhD, Wroclaw Medical University, Wroclaw, Poland, discusses current and future strategies for the management of acute and chronic graft-versus-host disease (GvHD) in patients undergoing allogeneic stem cell transplantation (alloSCT). In recent years, significant progress has been made in the treatment of GvHD due to the introduction of ruxolitinib and extracorporeal photopheresis, and Dr Czyz anticipates further improvements in GvHD management with belumosudil and anti-integrin therapies. This interview took place at the EBMT-EHA 6th European CAR T-cell Meeting in Valencia, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Anna Czyz

1:09
The role of alloSCT in LBCL in the era of CAR-T
Anna Czyz • 17 Feb 2024
1:57
Diminished chronic GvHD symptoms following anti-CD19 CAR T-cell therapy: a case study
Anna Czyz • 17 Feb 2024

Related Videos

4:33
The EBMT Patient Advocacy Committee: Patient, Family and Donor Day at EBMT 2024
Natacha Bolaños • 16 Apr 2024
2:55
Distinguishing late-onset neutropenia from classical primary neutropenia
Carlo Dufour • 15 Apr 2024
2:39
The MAGIC algorithm probability to predict outcomes of GvHD in the GI tract
James Ferrara • 16 Apr 2024
2:25
The EBMT Trainee Committee: in-person trainee day at EBMT 2024 and upcoming initiatives
Claire Horgan • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals